The company says the relocation is one of a number of strategic initiatives designed to support its mission to become a premiere biopharmaceutical company focused on the development and commercialization of bioactive peptides as new prescriptive pharmaceuticals for the treatment of life-threatening disease. The company's New Orleans space did not provide for laboratory facilities, and the lease was allowed to expire.
The Helix BioMedix, Inc. scientific teams have developed a large library of proprietary synthetic peptides and are pursing opportunities for their commercialization as anti-infective, anti-cancer and wound healing agents.
The relocation will maximize the involvement of the Company's recently constituted Scientific Advisory Board (SAB). Members of this Board are prominent scientists expert in discovery and commercialization of various classes of antimicrobial peptides. This board brings a blend of academic, scientific and biotechnology/pharmaceutical industry expertise to Helix BioMedix.
Steve Beatty, president and chief executive officer, says, "The synergy achieved by relocation will assist the company and its chief scientific officer, Dr. Timothy J. Falla, in expanding our existing and future partnerships with recognized academic and industry scientific leaders in the Pacific Northwest and Canada. We are looking forward to becoming an active member of the biotechnology community in the greater Seattle region."
Representatives of the Broderick Group brokered the deal for the company.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
